Please use this identifier to cite or link to this item:
Title: Systemic treatment of renal cell cancer: A comprehensive review.
Authors: Sánchez-Gastaldo, Amparo
Kempf, Emmanuelle
González Del Alba, Aránzazu
Duran, Ignacio
Keywords: Angiogenesis;Immunotherapy;Monoclonal antibody;Renal cell cancer;Targeted therapy;Tyrosine-kinase inhibitor;mTOR inhibitor
metadata.dc.subject.mesh: Antineoplastic Agents
Carcinoma, Renal Cell
Kidney Neoplasms
Molecular Targeted Therapy
Issue Date: 1-Sep-2017
Abstract: Kidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments.
metadata.dc.identifier.doi: 10.1016/j.ctrv.2017.08.010
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons